BGD — Biogened SA Income Statement
0.000.00%
Last trade - 00:00- PLN49.13m
- PLN63.46m
- PLN113.11m
Annual income statement for Biogened SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | PAS | PAS | PAS | PAS | PAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 65.3 | 79.6 | 95.6 | 111 | 113 |
| Cost of Revenue | |||||
| Gross Profit | 42.3 | 57.4 | 63.5 | 76.7 | 72.1 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 61.5 | 71.2 | 86.5 | 102 | 104 |
| Operating Profit | 3.87 | 8.41 | 9.04 | 9.38 | 8.68 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3.61 | 6.39 | 6.89 | 6.84 | 6.07 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.24 | 3.38 | 5.1 | 4.97 | 5.02 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.24 | 3.38 | 5.1 | 4.97 | 5.02 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.96 | 3.38 | 5.1 | 5.82 | 4.94 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.798 | 1.37 | 1.81 | 2.28 | 1.87 |
| Dividends per Share |